ReviewInternational journal of molecular sciences2020
Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Iran's Escherichia coli AMR Landscape (2010-2025): A One Health Systematic Review and Meta-Analysis.MicrobiologyOpen · 2026Pooled it
- Neglected ESKAPE Pathogens in Companion Animals: Diagnostic Bias, Zoonotic Blind Spots, and Phytotherapeutic Opportunities.Pathogens (Basel, Switzerland) · 2026Review
- Artificial Intelligence-Driven Discovery and Optimization of Antimicrobial Peptides Targeting ESKAPE Pathogens and Multidrug-Resistant Fungi.Microorganisms · 2026Review
- Genomic characterization and multidrug resistance ofVeterinary world · 2025Article
- Exploring the Role of Berberine as a Molecular Disruptor in Antimicrobial Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Adaptations of Bacterial Extracellular Vesicles in Response to Antibiotic Pressure.International journal of molecular sciences · 2025Review
- Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.Infectious diseases and therapy · 2025Review
- Promising Antimicrobial Activities of Essential Oils and Probiotic Strains on Chronic Wound Bacteria.Biomedicines · 2025Article
- Promising Future of Novel Beta-Lactam Antibiotics Against Bacterial Resistance.Drug design, development and therapy · 2025Review
- Article
- Antimicrobial resistance inScience in One Health · 2025Review
- Fabrication of Co-Assembly from Berberine and Tannic Acid for Multidrug-Resistant Bacteria Infection Treatment.Pharmaceutics · 2023Article
- Review
- A Tale of Two Pandemics: Antimicrobial Resistance Patterns ofAntibiotics (Basel, Switzerland) · 2023Article
- Isolation and identification of bioactive compounds from Antrodia camphorata against ESKAPE pathogens.PloS one · 2023Article
- Article
- Designing Anti-Microbial Peptides Against Major β-Lactamase Enzymes in Clinically Important Gram-Negative Bacterial Pathogens: An In-Silico Study.Probiotics and antimicrobial proteins · 2022Article
- Membrane Transporters Involved in the Antimicrobial Activities of Pyrithione inMolecules (Basel, Switzerland) · 2021Article
- Hemolytic Activity, Cytotoxicity, and Antimicrobial Effects of Human Albumin- and Polysorbate-80-Coated Silver Nanoparticles.Nanomaterials (Basel, Switzerland) · 2021Article
- Present and Future Perspectives on Therapeutic Options for Carbapenemase-ProducingMicroorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Since the discovery of penicillin by Alexander Fleming in 1929 as a therapeutic agent against staphylococci, β-lactam antibiotics (BLAs) remained the most successful antibiotic classes against the majority of bacterial strains, reaching a percentage of 65% of all medical prescriptions. Unfortunately, the emergence and diversification of β-lactamases pose indefinite health issues, limiting the clinical effectiveness of all current BLAs. One solution is to develop β-lactamase inhibitors (BLIs) capable of restoring the activity of β-lactam drugs. In this review, we will briefly present the older and new BLAs classes, their mechanisms of action, and an update of the BLIs capable of restoring the activity of β-lactam drugs against ESKAPE (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.